Lilly Launches Foundayo in the UK as NICE Review Continues

Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is available.

The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch gives Lilly an oral alternative to its injectable treatments, but access through England’s state-run National Health Service will depend on a separate review.

Bull Case

Foundayo’s UK launch marks an important step in Lilly’s effort to expand its presence in the market for metabolic treatments. It is authorised for both weight management and type 2 diabetes, allowing the company to address two related but distinct patient groups with the same oral medicine. A pill may also appeal to eligible patients who would prefer an oral treatment over an injection. That could help Lilly reach people who have been hesitant to begin an injectable therapy, although the supplied information does not provide forecasts for patient demand or prescription volumes.

Pricing could strengthen the private-market proposition, as Lilly expects Foundayo to cost between £100 and £120 per month through private providers, compared with approximately £330 for a month’s supply of its Mounjaro injection. The comparison suggests Foundayo may offer a lower-cost entry point into Lilly’s portfolio, although the prices may not represent equivalent doses or directly comparable treatment regimens.

The UK launch also gives Lilly an early commercial presence while regulatory reviews continue elsewhere. Foundayo remains under review in the European Union, making Britain the first European market in which Lilly can begin building prescribing experience with the drug. International pricing provides additional context for the company’s strategy. In the United States, Foundayo’s self-pay price begins at $149 per month and can increase to $349 at higher doses. A new Medicare pilot also provides selective access to oral weight-management drugs for $50 per month.

Bear Case

The immediate limitation is that Foundayo is available only through private prescription. Before it can be offered through the NHS in England, the National Institute for Health and Care Excellence must assess whether the treatment provides sufficient value for the healthcare system, and that process has no clear completion date. NICE requested additional information about Foundayo following its first committee meeting, and no date has been scheduled for a second review. Lilly said it is working with the agency during its assessment of access for weight management, but there is no guarantee regarding either the outcome or timing.

Private availability may restrict the initial patient population to those able and willing to pay between £100 and £120 per month. Even though that expected price is below the stated private cost of Mounjaro, it still represents a recurring personal expense. Foundayo is also the second GLP-1 tablet launched in the UK, following Novo Nordisk’s Wegovy pill. Private providers offer the initial lower doses of the Wegovy pill for approximately £74 to £129 per month, generally through multi-month subscription arrangements, with prices increasing at higher doses. Foundayo therefore enters an oral market that already offers patients another option.

The European rollout remains uncertain as well. Foundayo is still under EU review, so the UK launch does not yet provide broader access across the region.

Conclusion

Launching Foundayo in Britain gives Lilly its first European market for the oral treatment and provides eligible patients with another privately available option for weight management and type 2 diabetes. Its expected pricing could also make it less expensive than Lilly’s Mounjaro injection in the UK private market.

The larger opportunity, however, depends on access beyond private prescriptions, and NICE’s review and its request for additional information mean that the timing of NHS availability remains uncertain. For investors, the UK launch is commercially meaningful, but broader adoption will depend heavily on reimbursement decisions and the eventual European regulatory outcome.

READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? 

This article is originally published at Insider Monkey.